INVO Fertility, Inc. (IVF)
| Market Cap | 2.79M |
| Revenue (ttm) | 6.59M |
| Net Income (ttm) | -25.15M |
| Shares Out | 2.16M |
| EPS (ttm) | -41.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,333 |
| Open | 1.250 |
| Previous Close | 1.250 |
| Day's Range | 1.250 - 1.290 |
| 52-Week Range | 1.250 - 17.040 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2025 |
About IVF
INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in... [Read more]
Financial Performance
Financial StatementsNews
INVO Fertility Expands Telehealth Capabilities at Its Wisconsin Fertility Institute
MIDDLETON, Wis. and SARASOTA, Fla.
INVO Fertility's Wisconsin Clinic Recognized on Newsweek's List of America's Best Fertility Clinics for 2025
MIDDLETON, Wis. and SARASOTA, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access...
INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced...
INVO Fertility Announces First Quarter 2025 Financial Results
Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya Therapeutics Company now exclusively focused on the growing fer...
INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted EBITDA
SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanc...
INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF”
SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to...
NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”
Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients ...
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment
NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared INVOcell Technology NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared IN...
NAYA Biosciences Announces Nomination of New Board Members
SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in onco...